| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9452 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 5993 | 2017 |
| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4680 | 2014 |
| Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers H Li, KB Chiappinelli, AA Guzzetta, H Easwaran, RWC Yen, R Vatapalli, ... Oncotarget 5 (3), 587, 2014 | 438 | 2014 |
| PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), 2019 | 413 | 2019 |
| The future of epigenetic therapy in solid tumours—lessons from the past N Azad, CA Zahnow, CM Rudin, SB Baylin Nature reviews Clinical oncology 10 (5), 256-266, 2013 | 386 | 2013 |
| Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity NS Azad, EM Posadas, VE Kwitkowski, SM Steinberg, L Jain, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 380 | 2008 |
| Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study M Javle, MJ Borad, NS Azad, R Kurzrock, GK Abou-Alfa, B George, ... The lancet oncology 22 (9), 1290-1300, 2021 | 237 | 2021 |
| Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, N Azad, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 20 (10), 1139-1167, 2022 | 232 | 2022 |
| Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease MM Boyiadzis, JM Kirkwood, JL Marshall, CC Pritchard, NS Azad, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 229 | 2018 |
| Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ... Journal of the National Cancer Institute 106 (6), dju089, 2014 | 219 | 2014 |
| Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study MA Lowery, HA Burris, F Janku, RT Shroff, JM Cleary, NS Azad, L Goyal, ... The lancet Gastroenterology & hepatology 4 (9), 711-720, 2019 | 199 | 2019 |
| Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival L Danilova, WJ Ho, Q Zhu, T Vithayathil, A De Jesus-Acosta, NS Azad, ... Cancer immunology research 7 (6), 886-895, 2019 | 192 | 2019 |
| Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases G Karagkounis, MS Torbenson, HD Daniel, NS Azad, LA Diaz Jr, ... Cancer 119 (23), 4137-4144, 2013 | 192 | 2013 |
| Colorectal cancer in the young: epidemiology, prevention, management RL Siegel, CD Jakubowski, SA Fedewa, A Davis, NS Azad American Society of Clinical Oncology Educational Book 40, e75-e88, 2020 | 191 | 2020 |
| Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors E Sausville, P LoRusso, M Carducci, J Carter, MF Quinn, L Malburg, ... Cancer chemotherapy and pharmacology 73, 539-549, 2014 | 189 | 2014 |
| Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future ES Christenson, E Jaffee, NS Azad The Lancet Oncology 21 (3), e135-e145, 2020 | 176 | 2020 |
| An analysis of genetic heterogeneity in untreated cancers JG Reiter, M Baretti, JM Gerold, AP Makohon-Moore, A Daud, ... Nature Reviews Cancer 19 (11), 639-650, 2019 | 175 | 2019 |
| Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy NS Azad, JB Aragon-Ching, WL Dahut, M Gutierrez, WD Figg, L Jain, ... Clinical Cancer Research 15 (4), 1411-1416, 2009 | 167 | 2009 |
| Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the … DK Reyes, JA Vossen, IR Kamel, NS Azad, TA Wahlin, MS Torbenson, ... The Cancer Journal 15 (6), 526-532, 2009 | 163 | 2009 |
